Modality
Fusion Protein
MOA
PRMT5i
Target
PD-L1
Pathway
Incretin
LGS
Development Pipeline
Preclinical
~Feb 2024
→ ~May 2025
Phase 1
Aug 2025
→ May 2025
Phase 1Current
NCT04667068
2,429 pts·LGS
2025-08→2025-05·Completed
2,429 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-05-2110mo agoPh2 Data· LGS
Trial Timeline
Q3
P1/2
Complet…
Catalysts
Ph2 Data
2025-05-21 · 10mo ago
LGS
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04667068 | Phase 1/2 | LGS | Completed | 2429 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP |